We found that chronic lymphocytic leukemic (CLL) B cells are highly sensitive to infection with vectors derived from replication-defective herpes simplex virus-1 (rdHSV-1). CLL B cells were found to express high levels of herpes virus entry mediator (Hve) A, but not HveC, the other known receptor for HSV-1. An HveA cDNA from CLL cells was found to encode Arg→Lys and Val→Iso substitutions at amino acids 17 and 241, respectively. Nevertheless, this cDNA encoded a functional receptor for HSV-1 when transfected into Chinese hamster ovarian (CHO) cells. Antibodies to HveA could block rdHSV-1 infection of CLL cells and HveA-transfected CHO cells with similar efficiencies in vitro.
Introduction
B cell chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western societies. At present there is no cure, mandating improved treatment modalities. 1 Vectors that can mediate gene transfer will allow for development of new therapeutic strategies. 2 Adenovirus vectors can be used to transfer genes into CLL B cells. 3 However, because CLL B cells lack the fiber receptor necessary for adenovirus attachment, infection of CLL B cells with adenovirus vectors is not efficient and requires high numbers of viral particles per cell. Nevertheless, the ability of adenovirus vectors to transfer genes into CLL B cells has allowed for clinical trials in gene therapy. 4 Development of more efficient vectors for transgene expression in CLL B cells could facilitate efforts to develop gene therapy for this disease.
Herpes simplex virus-type I (HSV-1) is an excellent candidate for use as a vector for gene transfer into CLL B cells. HSV-1 has a broad host range and can infect resting post-mitotic cells. HSV-1 infection is mediated by envelope glycoproteins B and/or C binding to glycosaminoglycan chains of cell surface proteoglycans, [5] [6] [7] followed by entry via the herpes virus entry mediators (Hve), HveA or HveC. [8] [9] [10] [11] [12] HveA, otherwise called HVEM, In contrast to B cells of normal donors, CLL B cells were resistant to the cytopathic effects of infection by rdHSV-1 and maintained high-level expression of the transgene for several days in vitro. We propose that this is due to the expression by CLL cells of the anti-apoptotic protein, bcl-2. Consistent with this, we found that transduction of HeLa cells with a retrovirus expression vector encoding bcl-2 rendered HeLa cells resistant to the cytopathic effects of rdHSV-1. HSV-1-derived vectors should be excellent vehicles for gene transfer into CLL B cells, allowing for its potential use in gene therapy for this disease. Gene Therapy (2000) 7, 1210-1216.
TR2, 14 or ATAR, 15 is a type I transmembrane protein that is a member of the tumor necrosis factor receptor superfamily. The HSV-1 glycoprotein D has been shown to bind directly to HveA and HveC cell surface receptors. 10, 16 In this study we examined the relative susceptibility of CLL B cells to transduction using vectors derived from HSV-1. For these studies we used a replication-defective HSV-1 expression vector, Cgal⌬3, that encodes lacZ. 17, 18 This allowed us to monitor for infection and expression of the lacZ transgene by examining infected cells for their expression of ␤-galactosidase (␤-gal) by flow cytometry.
Results

CLL B cells (CLL cells)
were infected with Cgal⌬3 at various multiplicity of infection (MOI) ratios and the levels of ␤-gal activity were assessed 24 h later via flow cytometry. We found that the proportion of CLL cells having detectable ␤-gal activity increased with increasing amounts of virus vector. Infection of CLL cells with Cgal⌬3 at an MOI of 0.1 resulted in a transduced cell population of which greater than 25% expressed highlevels of the lacZ transgene (mean 25% ± 12.1% s.d., n = 6) (Figures 1 and 2) .
We compared relative sensitivity to infection of CLL cells with that of HeLa cells or Vero cells. We found that HeLa cells or Vero cells required approximately 10-fold greater amounts of Cgal⌬3 than that required by CLL cells to express the lacZ transgene (Figure 2 ). In addition, the relative levels of ␤-gal expressed in HeLa cells after transduction with saturating amounts of Cgal⌬3 was significantly lower than that achieved in CLL cells (data not shown). Transduction of normal non-neoplastic B cells also resulted in levels of ␤-gal expression similar to that of CLL B cells (data not shown). As such, the high sensitivity to infection by HSV-1 is not a property unique to transformed B cells.
We examined CLL cells for expression of HveA or HveC. These cell surface proteins can function as receptors that facilitate HSV-1 virus entry into cells. Using HveA primer sequences we were able to amplify HveA from cDNA generated from CLL cells. In contrast, oligonucleotide primers specific for HveC failed to generate a PCR product from cDNA made from CLL cells (data not Gene Therapy shown). These same oligonucleotide primers, however, were able to generate a HveC PCR product from the cDNA generated from HeLa (data not shown).
Using antisera specific for human HveA and flow cytometry, we observed relatively high levels of HveA expression on CLL cells (Figure 3 ). The average mean fluorescence intensity ratio (MFIR) for HveA on CLL cells was 2.9 (± 0. Comparison of the primary sequence of the HveA cDNA cloned from CLL B cells with that of the published HveA sequence revealed two non-conservative substitutions. One resulted in an arginine to lysine substitution at position 17, and the other generated a valine to isoleucine substitution at amino acid 241. 13 Nevertheless, Chinese hamster ovarian (CHO) cells transfected with CLL-derived HveA cDNA (CHO-HveA) were sensitive to infection with HSV-1, in contrast to nontransfected CHO cells (Figure 4 ).
To test whether Cgal⌬3 infection of CLL or CHO-HveA cells was dependent upon HveA, we incubated these cells with increasing amounts of anti-HveA antisera before the addition of Cgal⌬3. Infection of both CLL cells and CHO-HveA cells was inhibited in a dose-dependent manner (Figure 5a and b). In contrast, such antisera could not inhibit HSV-1 infection of HeLa or Vero cells, even at the lowest serum dilution (data not shown). Similarly, pretreatment of CLL cells with pre-immune rabbit serum had no effect upon the infection efficiency of Cgal⌬3 ( Figure 5 ).
Cgal⌬3 infection of CLL cells from any one of eight different patients resulted in high levels of ␤-gal expression over time. Cgal⌬3 infection of CLL cells resulted in detectable expression of ␤-gal as early as 4 h after infection at an MOI of 1. The level of ␤-gal expression continued to rise, reaching a maximum at 48-72 h following the addition of the virus. Surprisingly, 
Figure 5 Inhibition of Cgal⌬3 infection by anti-HveA antisera. CLL cells (a) and CHO cells transfected with pcCLL-HveA (b) were incubated for 1 h with the indicated concentrations of either pre-immune rabbit serum or rabbit anti-HveA serum before Cgal⌬3 infection. A MOI ratio of 1 was used for CLL infection and a MOI ratio of 10 was used for CHO cells. The percentage of cells positive for ␤-gal enzymatic activity was determined by flow cytometry analysis 48 h after infection.
expression of ␤-gal in Cgal⌬3-infected CLL cells could be detected for at least 9 days after infection ( Figure 6 , and data not shown). Moreover, we did not observe any reduction in the viability of infected CLL cells relative to that of control non-infected CLL cells (Figure 7 ). This contrasts with the known cytopathic effects of replication-defective HSV-1 vectors, such as Cgal⌬3. 17 Typi- 
Figure 7 Viability of normal B cells and CLL cells following infection with Cgal⌬3. CLL cells (n = 6) or normal B cells (n = 2) alone or infected with Cgal⌬3 at a MOI ratio of 1. The cell viability was determined by staining the cells with propidium iodide before flow cytometric analysis at the times indicated. Error bars indicate the standard deviations.
cally, infection of cells with Cgal⌬3 induces apoptosis of normal cells, including CHO-HveA or HeLa cells within 48 h after infection (data not shown, and Table 1 ). The viability of normal B cells decreased 48 h after infection with Cgal⌬3, resulting in more than 90% cell death by 5 days (Figure 7 ). However, we did not observe any decrease in viability of Cgal⌬3-infected CLL cells over that of mock-infected CLL cells of any patient (n = 8), for as long as 9 days after infection, at which point the experiment was stopped ( Figure 7 ). The resistance of CLL cells to the cytopathic effects of HSV-1 may be due to the noted high-level expression of bcl-2 by CLL cells.
19-21
We performed limiting dilution analyses to study the effect of bcl-2 on the cloning efficiency of Cgal⌬3-infected (Table 1) . However, Cgal⌬3-infected HeLa-bcl-2 cells had a relative cloning efficiency of 82.3 ± 1% compared with that of noninfected HeLa-bcl-2 cells (Table 1) . We conclude that expression of bcl-2 can protect HeLa cells from the cytopathic effect of Cgal⌬3 and allow for the generation of daughter cells after infection.
Discussion
We found that CLL B cells are highly sensitive to transduction by HSV-1 vectors. In some cases, all the leukemia cells in a given population could be made to express a transgene at MOI ratios of less than 0.3 ( Figure 1 ). Moreover, in all cases, nearly all of the CLL cells could be made to express an HSV-1-encoded transgene at an MOI ratio of 1 (data not shown). The MOI ratio is determined by testing each rdHSV-1 preparation for its ability to develop plaques on E5, which are Vero cells that can complement the genetic defects in the rdHSV-1. Because MOI ratios of less than 1 could infect virtually all leukemia cells, CLL cells appeared more permissive to infection with rdHSV-1 than E5, HeLa, or Vero cells ( Figure  2) . Consistent with this, we noted that proportions of CLL cells that expressed the transgene were significantly greater than that of HeLa cells at any given MOI ratio ( Figure 2 ). In contrast, the relative sensitivity for infection of CLL cells for adenovirus vectors is significantly less than that noted for HeLa or 293 cells, the cells used to
Gene Therapy propagate adenovirus vectors in vitro. 3 As such, HSV-1-derived vectors are relatively efficient vehicles for effecting gene transfer into CLL cells.
The high efficiency transduction achieved with rdHSV-1 in CLL may be similar to that noted for vectors derived from HSV-2 on hematopoietic cells. 22 A high proportion of CD34
+ marrow cells and acute leukemia cells could be made to express a transgene at MOI ratios of less than 1. Again, because such viruses are propagated on modified Vero cells this reflects the high relative sensitivity of hematopoietic cells for infection by HSV-2 relative to other cell types. Similarly, we noted that normal B cells, T cells, precursor B cell lines, and acute lymphocytic leukemia cells were also highly sensitive to infection with vectors derived from HSV-1 (data not shown). Collectively, these data indicate that HSV in general has the potential for making excellent vectors for gene transfer into hematopoietic cells and leukemias.
Despite belonging to the same family, HSV-1 and HSV-2 use different receptors to mediate cell entry. Whereas HveB (Prr2) appears to serve as a predominant receptor for HSV-2 type virus, 11 HSV-1 uses HveA (otherwise called HVEM, TR2 or ATAR) or HveC. 9, 23, 24 In many cell types, HveC appears to be the prominent receptor for HSV-1.
However, we found CLL cells express high levels of HveA (Figure 3 ), but negligible amounts of HveC, as assessed by RT-PCR (data not shown). The HveA cDNA isolated from CLL cells was found to have two non-conservative base substitutions from that of the known HveA. Conceivably, such changes reflect a genetic polymorphism in HveA, as has been noted for HveA by other investigators. 25 In any case, one base change resulted in an arginine to lysine substitution at amino acid position 17 within the leader polypeptide, while the other resulted in a valine to isoleucine change at position 241 in the cytoplasmic domain. The change in the leader polypeptide did not affect surface expression of HveA and change in the cytoplasmic domain should not affect the relative binding activity of HveA for HSV-1. Consistent with this, transfection of CHO cells with CLL-derived HveA rendered these cells highly sensitive to infection by HSV-1.
That HveA served as the predominant, if not sole, receptor for HSV-1 in CLL is indicated by our blocking studies, in which infection could be inhibited completely by anti-HveA antisera. Moreover, the efficiency at which such antisera inhibited HSV-1 infection of CLL cells was similar to that at which they inhibited infection of CHO cells transfected with CLL-derived HveA cDNA ( Figure  5 ). In contrast, such antibodies could not inhibit HSV-1 infection of Vero cells (data not shown). We conclude that expression of HveA is both necessary and sufficient for the high sensitivity of CLL cells to infection with HSV-1. These observations have implications for the biology of HSV-1 infection in patients with CLL. Patients with this disease can develop painful lymphadenitis secondary to infection with HSV-1, even in the absence of mucocutaneous herpetic lesions. 26 In view of the current study, it is conceivable that this condition results from the direct infection of CLL cells by HSV-1. On the other hand, antibodies that block the interaction between HSV-1 and HveA may inhibit the de novo infection of CLL cells. The development of such antibodies could mitigate the ability of HSV-1, or HSV-1-derived vectors, to infect CLL cells, or to effect gene transfer into such cells in vivo.
Once infected, however, CLL cells appear resistant to the cytopathic effects of rdHSV-1. The rdHSV-1 vector used in these studies, Cgal⌬3, expresses four immediateearly genes and is cytotoxic to most cell types, including HeLa cells (Table 1) . 17 Moreover, infection of normal lymphocytes with Cgal⌬3 results in transient high-level transgene expression and then apoptosis within 48-96 h after infection (Figure 7 and data not shown). CLL cells infected with Cgal⌬3, on the other hand, appear resistant to this cytopathic effect and have a viability at 96 h after infection that is not significantly different from that of non-infected CLL cells in vitro (Figure 7 ). This feature allows the infected CLL cells to express high levels of transgene with little or no relative reduction in viability ( Figure 6 ).
The resistance of these leukemia cells to the cytopathic effect of Cgal⌬3 is probably due to the noted high-level expression of bcl-2 by the CLL B cells. 19, 27, 28 Bcl-2 has been shown by Wang and colleagues 29 to suppress the cytotoxic effect of rdHSV-1 vectors in PC12 cells. However, it was not determined whether expression of bcl-2 by PC12 cells inhibited apoptosis induced by infection with rdHSV-1 or merely delayed the cytopathic effect, allowing for prolonged expression of the HSV-encoded transgene.
We performed limiting dilution analyses to evaluate the relative cloning efficiencies of Cgal⌬3-infected HeLa cells transduced with a bcl-2 expression vector or a control vector. This minimized the possibility that surviving cells in long-term cultures were descendent from those that had escaped initial infection. We found that HeLa cells transduced to express bcl-2 had a cloning efficiency similar to that of non-infected HeLa cells. In contrast, HeLa cells that were not transduced to express bcl-2 had significantly lower cloning efficiency following infection with Cgal⌬3. We conclude from these studies that expression of bcl-2 is sufficient to allow for cells to survive and to generate daughter cells following infection with Cgal⌬3.
In conclusion, we find that CLL cells are highly sensitive to infection with HSV-1 and that this is dependent upon expression of HveA. In addition, CLL cells are resistant to the cytopathic effect of Cgal⌬3, and that this resistance most probably is due to the high level of bcl-2 expressed by the leukemia cells. Because such rdHSV-1-derived vectors can transfer genes so efficiently into CLL cells without inducing a cytopathic effect, Cgal⌬3 appears to be an excellent candidate vector for use in the gene therapy of this hematologic malignancy.
Materials and methods
Antibodies and reagents Dr P Spear (University of Pennsylvania) provided the rabbit anti-HveA antiserum and pre-immune serum. Fluorescein-isothiocyanate (FITC)-conjugated goat antirabbit antibodies (Southern Biotechnology Associates, Birmingham, AL, USA) were used to stain cells previously incubated with the anti-HveA antiserum or preimmune rabbit serum before flow cytometry. Fluorochrome-labeled mAbs specific for human CD19 were purchase from PharMingen (San Diego, CA, USA).
Cells and culture conditions
After informed consent, blood was obtained from normal adult donors or from patients satisfying diagnostic criteria for B cell CLL. 1 Mononuclear cells were isolated via density gradient centrifugation using Histopaque 1077 (Sigma Chemical, St Louis, MO, USA). B cells were isolated from the mononuclear cells of normal donors using Dynal beads (Dynal, Lake Success, NY, USA) coated with anti-CD19 mAbs. The cells were detached from the magnetic beads after positive selection using DETACHaBEAD (Dynal), as per the manufacturer's instructions. Chinese hamster ovarian cells (CHO), HeLa, E5 and Vero cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). E5 cells were used only for the propagation of Cgal⌬3 (see below). The cells were cultured at 37°C in 5% CO 2 in air, in culture medium consisting of RPMI-1640 (BioWhittaker, Parkville, MD, USA), containing 10% fetal calf serum (Gibco BRL, Gaithersburg, MD, USA), 2 mm l-glutamine (Gibco), 100 U/ml penicillin (Gibco), and 100 g/ml streptomycin (Gibco).
Virus vectors
Amphotropic Moloney murine leukemia (MoMLV) containing the gene coding for resistance to neomycin (MoMLV-neo) or the genes coding for neomycin resistance and bcl-2 (MoMLV-bcl-2), were obtained from the core laboratory of the UCSD Human Gene Therapy Program. Retroviral particles were produced from 293GP cells, as described.
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Cgal⌬3 is an ICP4-deletion mutant derived from D30EBA. 18, 31 It contains the Escherichia coli lacZ gene under the control of the human cytomegalovirus (CMV) promoter/enhancer within the short unique portion of the HSV-1 genome. Cgal⌬3 was propagated and assessed for its relative concentration of plaque-forming units (p.f.u.) on E5 cells, a cell line derived from Vero cells that had been transfected with HSV-1 ICP4. 31, 32 The MOI ratio provides the number of p.f.u. relative to the number of cells infected.
RT-PCR and cloning of HveA
The cDNA was generated from leukemia cells of a patient with CLL, as described. 33 The oligonucleotides, corre-sponding to the sense (dGTCTGGATCCGCCTGA GGCATGGAGCCTC) or antisense (dGTCTCTCGAG GTCAGTGGTTTGGGCTCCTC) strand flanking the known HveA coding region 13 were synthesized by Integrated DNA Technologies (Coralville, IA, USA), for use in PCR, as described. 33 The PCR product was isolated, digested with BamHI and XhoI (Gibco BRL), to digest flanking restriction sites, and then directionally cloned into pcDNA3 (Invitrogen, San Diego, CA, USA). HveC oligonucleotides, corresponding to the sense (dAGG CAGGCATCCCCCAGCACCA) or antisense (dCTCT CTCGAGCTACACGTACCACTCCTTCTT) strand of the known HveC coding region, 12 were synthesized (Integrated DNA Technologies) and used for RT-PCR analysis.
Transfection and transduction CHO cells were transfected with CLL-derived HveA cDNA cloned into pCDNA3 (Invitrogen) via calcium phosphate precipitation to generate CHO-HveA, as described. 34 HeLa cells were transduced with MoMLVneo or MoMLV-bcl-2, as described. 30 After overnight culture, the transfected cells were selected in culture medium containing 400 g/ml G418 (Geneticin; Gibco BRL). Nontransfected cells were selected in parallel to confirm their sensitivity to G418. Resistant cells were subcloned via limiting dilution in culture medium containing G418.
For infection studies with Cgal⌬3, 10 5 cells per well were infected at various MOI in 1 ml of culture medium. After 1 h at 37°C, the cells were washed and then placed in culture medium or used directly for analyses. Similarly, HeLa-bcl-2 or HeLa-neo cells were infected with Cgal⌬3 at a MOI of 10 for 1 h, washed, and then plated at various cell concentrations into separate wells of 96-well microtiter plates (Costar, Corning, NY, USA) for limiting dilution analyses. Aliquots of the infected cells were cultured for 24 h and then used to confirm expression of ␤-gal by flow cytometry.
Flow cytometry
To assess intracellular ␤-gal activity we used the ␤-gal fluorescent substrate fluorescein di-B-d-galactopyranoside (FDG) (Molecular Probes, Eugene, OR, USA). Expression of ␤-gal was determined using FDG and flow cytometric analysis, as described. 35 In brief, the cells were washed in staining media (SM) consisting of RPMI-1640, 3% fetal calf serum, and 0.05% sodium azide. The cells were suspended in 100 l SM and incubated for 10 min at 37°C before adding 100 l of 2 mm FDG in triple-distilled H 2 O. After 1 min at 37°C, we added 2 ml of icecold SM containing 20 ng propidium iodide, which was then analyzed using a FACS-Calibur (Becton Dickinson, San Jose, CA, USA).
To examine for expression of HveA, cells were incubated with normal goat serum before to the addition of the polyreactive anti-HveA antibodies to inhibit nonspecific binding. Subsequently, the cells were incubated in rabbit anti-HveA antiserum or pre-immune rabbit serum in SM. After 30 min at 4°C, cells were washed twice in SM and then stained with the FITC-conjugated goat antirabbit Ig. After 30 min at 4°C, cells were washed with SM containing propidium iodide and then analyzed. Dead cells and debris were detected by their characteristic forward-and side-light-scatter profiles and inability Gene Therapy to exclude propidium iodide. We calculated the mean fluorescence intensity ratio (MFIR) to compare the relative staining intensities of two or more stained cell populations. The MFIR is the mean fluorescence intensity (MFI) of cells stained with anti-HveA antiserum and FITC-anti-rabbit Ig divided by the MFI of cells stained with pre-immune rabbit antiserum and FITC-anti-rabbit Ig. For example, CHO cells that do not express HveA had an average MFIR of 1.0 ± 0.1 (s.d., n = 3 experiments), whereas CHO cells transfected with CLL-derived HveA cDNA had an average MFIR of 2.8 ± 0.4 (s.d., n = 3).
